EchoSolv AS vs Tempus ECG-AF

Similar category, different focus. These tools serve overlapping but distinct needs. Comparability 60/100 Comparability is an AI-graded 0–100 score of how directly these two tools compete — higher means a more apples-to-apples comparison.

EchoSolv AS

by Echo IQ

Tempus ECG-AF

by Tempus AI, Inc.

AI Verdict

EchoSolv AS and Tempus ECG-AF are both FDA-cleared AI tools for cardiology, but they address distinct clinical needs. EchoSolv AS focuses on identifying patients at risk for severe aortic stenosis using echocardiogram measurements, while Tempus ECG-AF analyzes 12-lead ECGs to predict the risk of new-onset atrial fibrillation in older patients. Therefore, a healthcare provider would choose between them based on the specific cardiac condition they need to assess.

Choose EchoSolv AS if…

Choose EchoSolv AS if your primary goal is to efficiently and accurately identify patients at high risk for severe aortic stenosis from existing echocardiogram measurements. This tool is ideal for cardiology departments seeking to prioritize studies for closer review and streamline the diagnostic workflow for sAS, integrating seamlessly with PACS without requiring EMR integration.

View EchoSolv AS →

Choose Tempus ECG-AF if…

Choose Tempus ECG-AF if you need to proactively identify elderly patients (65+) at increased risk of developing new-onset atrial fibrillation within the next year using standard 12-lead ECGs. This solution is best suited for practices focused on early detection and preventative management of AF in a specific at-risk population, leveraging existing ECG data for timely follow-up.

View Tempus ECG-AF →

Reviewed by Pouyan Golshani, MD — Interventional Radiologist

Quick Comparison

Feature	EchoSolv AS	Tempus ECG-AF
Pricing	Unknown	Contact vendor
Deployment	Cloud-based	Software solution, integrated into healthcare facility systems with advanced cardiology algorithms.
BAA Available	Yes AI-estimated	Yes AI-estimated
FDA Status	Cleared AI-estimated	Yes AI-estimated
HIPAA	Yes AI-estimated	Yes AI-estimated

Head-to-Head

AI-generated assessment across six dimensions based on each tool's documented features and compliance posture. Grounded in public data — not a substitute for hands-on evaluation.

Usability

EchoSolv AS

EchoSolv AS emphasizes its design to fit existing PACS workflows without requiring EMR integration and offers ultra-fast risk detection under 3 seconds. This suggests a simpler, faster integration and a more streamlined user experience compared to Tempus ECG-AF, which integrates into healthcare facility systems but doesn't explicitly highlight the same level of minimal integration friction.

Clinical Value

Tie

Both tools are FDA-cleared and address significant cardiac conditions with high clinical relevance. EchoSolv AS aids in the accurate and efficient identification of severe aortic stenosis, a critical and often underdiagnosed condition. Tempus ECG-AF provides early risk identification for new-onset atrial fibrillation, enabling proactive management for a prevalent condition.

Pricing & Value

Tempus ECG-AF

Tempus ECG-AF clearly outlines CMS reimbursement availability with specific CPT codes and a Medicare rate, providing transparent and established financial value for healthcare facilities. EchoSolv AS mentions a subscription-based model and identified Miscellaneous Code 93799 for reimbursement, but provides fewer explicit, quantified efficiency gains or a direct Medicare rate.

Enterprise Readiness

Tie

Both tools demonstrate strong enterprise readiness with FDA clearance, HIPAA compliance, and BAA availability. EchoSolv AS offers cloud-based deployment and integrates with PACS without requiring EMR integration, simplifying adoption for some. Tempus ECG-AF is designed for integration into healthcare facility systems and is compatible with major ECG vendors, ensuring broad applicability.

Innovation

Tempus ECG-AF

While EchoSolv AS offers innovative measurement-based AI for severe AS detection, Tempus ECG-AF stands out for its predictive capability to identify patients at risk of developing new-onset atrial fibrillation within 12 months from a standard ECG. This forward-looking risk prediction, trained on a massive dataset of over 1.5 million ECGs, represents a significant advancement in proactive cardiac care.

Support & Docs

Tempus ECG-AF

Tempus AI is a larger, more established company with a broader portfolio of AI solutions, which typically correlates with more extensive and structured support resources and documentation for enterprise clients. EchoSolv AS, from a more specialized company, does not have readily available public information regarding its support and documentation offerings.

Feature-by-Feature

Detail beyond the Quick Comparison summary. For pricing, deployment, BAA, FDA, and HIPAA see the Overview tab.

Feature	EchoSolv AS	Tempus ECG-AF
Name	EchoSolv AS	Tempus ECG-AF
Company	Echo IQ	Tempus AI, Inc.
Primary Clinical Focus	Identify patients at risk for severe aortic stenosis (sAS)	Identify patients at increased risk of developing atrial fibrillation/flutter (AF) within the next 12 months
Input Data Type	Echocardiogram measurements (numerical measurements, not images)	12-lead ECG recordings
Target Patient Population	Not specified	Patients aged 65 or older without pre-existing AF, pacemakers, ICDs, or recent cardiac surgery
Key Technology/Method	AI-powered clinical decision support, measurement-based AI, guideline analysis	AI-based algorithm, trained on over 1.5 million ECGs

Videos

Demos, reviews, and walkthroughs featuring EchoSolv AS and Tempus ECG-AF.

Loading videos…

Videos need JavaScript to load. Search YouTube directly →

View all on YouTube

Frequently Asked Questions

What specific cardiac conditions do these AI tools help identify or predict?

EchoSolv AS is designed to analyze echocardiograms to identify patients at risk for severe aortic stenosis (sAS) with high accuracy and efficiency. Tempus ECG-AF analyzes 12-lead ECG recordings to identify patients aged 65 or older at increased risk of developing atrial fibrillation/flutter (AF) within the next 12 months.

What type of patient data is required for each tool's analysis?

EchoSolv AS uses measurement-based AI, analyzing numerical measurements from echocardiograms, not images. Tempus ECG-AF analyzes 12-lead ECG recordings collected at a healthcare facility.

Are there specific patient populations or exclusion criteria for using these tools?

EchoSolv AS is intended for patients 18 years or older who have an echocardiogram performed as part of routine clinical care. Tempus ECG-AF is intended for patients aged 65 or older without pre-existing AF, pacemakers, ICDs, or recent cardiac surgery.

How do these tools integrate into existing clinical workflows?

EchoSolv AS is designed to fit existing workflows, integrating with PACS without requiring EMR integration. Tempus ECG-AF is a software solution integrated into healthcare facility systems with advanced cardiology algorithms.

What kind of clinical insights or outputs do these tools provide to the physician?

EchoSolv AS provides AI-powered clinical decision support for severe AS probability, consistent guideline checks from measurements, and second reader support to help prioritize studies. Tempus ECG-AF detects signs associated with new onset Atrial Fibrillation (AF) within 12 months, with results interpreted in conjunction with other diagnostic information and clinical history.

Is there specific reimbursement available for using either of these tools?

CMS reimbursement is available for Tempus ECG-AF, with CPT codes 0764T and 0765T assigned to APC 5734, effective January 1, 2025, at a Medicare rate of $128.90. The provided information for EchoSolv AS does not specify current reimbursement codes, though Echo IQ is working on securing them.